Heron Therapeutics Reports Mixed Q1 2026 Results, Reaffirms Full-Year Guidance

summarizeSummary

Heron Therapeutics reported a 10.8% decline in total net revenue and a net loss for Q1 2026, but its Acute Care franchise saw strong growth. The company reaffirmed its full-year guidance and settled CINVANTI patent litigation.

check_boxKey Events

• Q1 2026 Financial Performance

  Total net revenue decreased 10.8% year-over-year to $34.7 million, resulting in a net loss of $8.1 million and negative Adjusted EBITDA of $0.7 million.

• Acute Care Franchise Growth

  Net revenue for the Acute Care franchise grew 32% year-over-year to $13.6 million, with ZYNRELEF up 27% to $10.2 million and APONVIE up 50% to $3.4 million.

• Oncology Franchise Decline

  Oncology Supportive Care net revenue decreased 26.3% to $21.1 million, primarily due to a 20.2% decline in CINVANTI and the planned wind-down of SUSTOL.

• Full-Year Guidance Reaffirmed

  The company reaffirmed its 2026 full-year guidance of $173–$183 million in net revenue and $10–$20 million in Adjusted EBITDA.

auto_awesomeAnalysis

Heron Therapeutics reported a decline in total net revenue and a net loss for Q1 2026, contrasting with a net income in the prior year. However, its Acute Care franchise, driven by ZYNRELEF and APONVIE, showed strong year-over-year growth. Management reaffirmed its full-year 2026 revenue and Adjusted EBITDA guidance, suggesting confidence in a recovery from Q1 seasonality and operational improvements. The settlement of CINVANTI patent litigation also removes a legal overhang.